Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.

ABSTRACT:

Background

Intensification of therapy may improve outcomes for patients with high-risk localized prostate cancer.

Objective

To provide long-term follow-up data from phase III RTOG 0521, which compared a combination of androgen deprivation therapy (ADT) + external beam radiation therapy (EBRT) + docetaxel with ADT + EBRT.

Design, setting, and participants

High-risk localized prostate cancer patients (>50% of patients had Gleason 9-10 disease) were prospectively randomized to 2 yr of ADT + EBRT or ADT + EBRT + six cycles of docetaxel. A total of 612 patients were accrued, and 563 were eligible and included in the modified intent-to-treat analysis.

Outcome measurements and statistical analysis

The primary endpoint was overall survival (OS). Analyses with Cox propo

SUBMITTER: Sartor O 

PROVIDER: S-EPMC10662642 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature